Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022
30 September 2022 - 6:05AM
Business Wire
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage
biotechnology company discovering and developing breakthrough
treatments for immune-mediated and oncologic disorders, today
announced that three posters will be presented at the upcoming
American College of Rheumatology (ACR) Convergence 2022, which will
take place November 10 – 14, 2022 in Philadelphia, PA. Of note, the
Phase 2 MISSION poster will include the full data set from the
concluded study, with all 17 evaluable patients completing the
37-week trial. There will be additional MISSION data included in
the poster presentation that are not available in the abstract.
Poster Presentation Details:
Abstract Title: Interim Results from the Phase 2 MISSION
Study Evaluating Zetomipzomib (KZR-616), a First-in-Class Selective
Immunoproteasome Inhibitor for the Treatment of Lupus Nephritis
Session: SLE – Treatment Poster II Date/Time:
November 13, 2022 from 9:00 AM - 10:30 AM ET Presenter: Amit
Saxena, MD, Assistant Professor, NYU School of Medicine
Abstract Title: Poor Health-Related Quality of Life in
Patients with Lupus Nephritis Session: Patient Outcomes,
Preferences, and Attitudes Poster II Date/Time: November 13,
2022 from 1:00 PM - 3:00 PM ET Presenter: Cristina Arriens,
MD, Clinical Associate Member, Arthritis & Clinical Immunology
Research Program, Oklahoma Medical Research Foundation
Abstract Title: Healthcare Resource Utilization and Costs
of Management of Lupus Nephritis in Adult and Juvenile Patients
with Systemic Lupus Erythematosus Poster Session: Health
Services Research Poster I: Lupus, RA, Spondyloarthritis and More
Date/Time: November 12, 2022 from 1:00 PM - 3:00 PM ET
Presenter: Kenneth Kalunian, MD, Professor of Medicine,
University of California San Diego
The accepted ACR abstracts are currently available on the
congress platform here. Following the conference, the presentation
materials will be available in the “Scientific Publications”
section of Kezar Life Science’s website at
www.kezarlifesciences.com.
About Zetomipzomib (KZR-616)
Zetomipzomib (KZR-616) is a novel, first-in-class, selective
immunoproteasome inhibitor with broad therapeutic potential across
multiple autoimmune diseases. Preclinical research demonstrates
that selective immunoproteasome inhibition results in a broad
anti-inflammatory response in animal models of several autoimmune
diseases, while avoiding immunosuppression. Data generated from
Phase 1 clinical trials provide evidence that zetomipzomib exhibits
a favorable safety and tolerability profile for development in
severe, chronic autoimmune diseases.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical
company discovering and developing breakthrough treatments for
immune-mediated and oncologic disorders. The company is pioneering
first-in-class, small-molecule therapies that harness master
regulators of cellular function to inhibit multiple drivers of
disease via single, powerful targets. Zetomipzomib, its lead
development asset, is a selective immunoproteasome inhibitor being
evaluated in a Phase 2 clinical trial in lupus nephritis. This
product candidate also has the potential to address multiple
chronic immune-mediated diseases. KZR-261 is the first anti-cancer
clinical candidate from the company’s platform targeting the Sec61
translocon and the protein secretion pathway. An open-label
dose-escalation Phase 1 clinical trial of KZR-261 to assess safety,
tolerability and preliminary tumor activity in solid tumors is
underway. For more information, visit
www.kezarlifesciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220929005862/en/
Investor Contact: Gitanjali Jain Vice President, Investor
Relations and External Affairs gjain@kezarbio.com Media
Contact: Julia Deutsch Solebury Strategic Communications
jdeutsch@soleburystrat.com
Kezar Life Sciences (NASDAQ:KZR)
Historical Stock Chart
From Apr 2024 to May 2024
Kezar Life Sciences (NASDAQ:KZR)
Historical Stock Chart
From May 2023 to May 2024